Journal article
Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: A substudy of the phase 3 ASPEN trial
M Dimopoulos, RG Sanz, HP Lee, M Trneny, M Varettoni, S Opat, S D'Sa, RG Owen, G Cull, S Mulligan, J Czyz, JJ Castillo, M Motta, T Siddiqi, MG Mesa, MG Gorrochategui, D Talaulikar, PL Zinzani, E Askari, S Grosicki Show all
Blood Advances | ELSEVIER | Published : 2020
Open access
Abstract
Patients with Waldenström macroglobulinemia (WM) lacking activating mutations in the MYD88 gene (MYD88WT) have demonstrated relatively poor outcomes to ibrutinib monotherapy, with no major responses reported in a phase 2 pivotal study. Zanubrutinib is a novel, selective Bruton tyrosine kinase (BTK) inhibitor designed to maximize BTK occupancy and minimize off-target activity. The ASPEN study consisted of a randomized comparison of zanubrutinib and ibrutinib efficacy and safety in patients with WM who have the MYD88 mutation, as well as a separate cohort of patients without MYD88 mutation (MYD88WT) or with unknown mutational status who received zanubrutinib. Results from the latter single-arm..
View full abstractGrants
Funding Acknowledgements
This study was supported by research funding from BeiGene Inc., US; and medical writing and editorial assistance were funded by BeiGene and provided by Gordon Bray and Bio Connections, LLC.